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Mutations in the gene encoding tau (MAPT) cause frontotemporal dementia spectrum disorders. A rare tau variant p.A152T was
reported as a risk factor for frontotemporal dementia spectrum and Alzheimer’s disease in an initial case-control study. Such
ﬁndings need replication in an independent cohort. We analysed an independent multinational cohort comprising 3100 patients
with neurodegenerative disease and 4351 healthy control subjects and found p.A152T associated with signiﬁcantly higher risk for
clinically deﬁned frontotemporal dementia and progressive supranuclear palsy syndrome. To assess the functional and biochemical
consequences of this variant, we generated transgenic zebraﬁsh models expressing wild-type or A152T-tau, where A152T caused
neurodegeneration and proteasome compromise. Impaired proteasome activity may also enhance accumulation of other proteins
associated with this variant. We increased A152T clearance kinetics by both pharmacological and genetic upregulation of autop-
hagy and ameliorated the disease pathology observed in A152T-tau ﬁsh. Thus, autophagy-upregulating therapies may be a strategy
for the treatment for tauopathies.
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Introduction
Neurodegenerative diseases are classiﬁed neuropathologi-
cally by the distribution and morphology of distinct protein
inclusions in the brain. Some diseases share a common
pathological protein suggesting potential pathophysio-
logical overlap, but features such as the morphology and
anatomical distribution of such inclusions deﬁne distinct
disease entities. For example, Alzheimer’s disease shows
both amyloid-b and microtubule-associated protein tau
(MAPT) in the form of neuritic plaques and neuroﬁbrillary
tangles, with clinical progression correlating exclusively
with neuroﬁbrillary tangle burden (Arriagada et al., 1992).
Frontotemporal lobar degeneration (FTLD) shows several
disease subtypes of tau pathology, including progressive
supranuclear palsy, corticobasal degeneration, and Pick’s dis-
ease (Neumann et al., 2009). Both Alzheimer’s disease and
FTLD caused by tau (FTLD-tau) feature tau inclusions
(Grundke-Iqbal et al., 1986; Hutton et al., 1998;
Spillantini et al., 1998); however, other forms of presenile
dementia with neuroﬁbrillary lesions but no amyloid-b de-
posits have also been described (Sumi et al., 1992; Spillantini
et al., 1996; Goedert, 2016), suggesting that neuroﬁbrillary
tangles frequently observed in early stages of Alzheimer’s
disease pathology can occur independently of amyloid-b de-
posits and are associated with dementia.
Although the known MAPT mutations appear to exclu-
sively cause FTLD-tau pathology, the rare p.A152T variant,
ﬁrst identiﬁed in a patient with dementia with behavioural
symptoms and unclassiﬁable tau pathology (Kovacs et al.,
2011), was identiﬁed as a genetic risk factor for both clinic-
ally-deﬁned Alzheimer’s disease and frontotemporal demen-
tia (FTD) spectrum disorders in an initial genetic association
study (Coppola et al., 2012). p.A152T is a single G4A
nucleotide change in a non-microtubule-binding region of
exon 7 in MAPT, and diminishes tau binding to microtu-
bules, while increasing tau oligomer formation (Coppola
et al., 2012). p.A152T carriers with neurodegenerative dis-
ease show heterogeneous clinical syndromes, including pro-
gressive supranuclear palsy syndrome (PSP-S), behavioural
variant FTD, non-ﬂuent variant primary progressive aphasia,
corticobasal syndrome, clinical Alzheimer’s disease, and de-
mentia with Lewy bodies (Lee et al., 2013b; Labbe et al.,
2015). The term ‘syndrome’ is used because the underlying
neuropathology for these disorders is variable, particularly
corticobasal syndrome. Together, these studies suggest that
p.A152T is a risk factor for diverse neurodegenerative dis-
ease syndromes related to FTLD-tau and possibly synuclei-
nopathy, although recently, a study of 11572 subjects in
Spain did not observe an increased association between
p.A152T and Alzheimer’s disease, while the association
with FTD spectrum approached signiﬁcance [odds ratio
(OR) = 2.03; P = 0.063] (Pastor et al., 2016).
To resolve whether p.A152T is a risk variant, we per-
formed a replication study to screen the p.A152T variant in
an independent multinational cohort consisting of 3100 pa-
tients with neurodegenerative disease and 4351 healthy con-
trol subjects. Furthermore, to assess whether the A152T-tau
showed greater toxicity than wild-type-tau in vivo, we gener-
ated new zebraﬁsh models expressing either wild-type or
A152T human tau, which revealed more neurodegeneration
and tau pathology in the disease-allele associated variant ﬁsh.
Previously we found that wild-type forms of tau, like many
other intracytoplasmic aggregate-prone proteins, can be
degraded by macroautophagy (henceforth autophagy), as
well as via the ubiquitin–proteasome pathway (Berger et al.,
2006; Moreau et al., 2014; reviewed in Lee et al., 2013a).
Autophagy involves the sequestration of portions of cyto-
plasm into double-membrane vesicles called autophagosomes,
which are then trafﬁcked to lysosomes that mediate the deg-
radation of the autophagosomes and their contents
(Rubinsztein, 2006; Rubinsztein et al., 2012). We found the
A152T variant to be associated with disruption of prote-
asome function and delayed tau clearance in vivo, whereas
autophagy function was unaffected. Hence, we assessed the
potential utility of autophagy upregulation to improve clear-
ance, and found that this could enhance the degradation of
A152T-tau in zebraﬁsh and ameliorate its toxicity, suggesting
a possible therapeutic strategy for these tauopathies.
Materials and methods
Participants
We included 3100 patients with neurodegenerative disease and
4351 controls recruited worldwide across collaborating
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centres, including: (i) University of California San Francisco
and the multicentre Davunetide trial (Boxer et al., 2014)
(Allon series); (ii) Gladstone Institute (Gladstone Turkish
series); (iii) University of Brescia and San Raffaele Scientiﬁc
Institute (Italian series); (iv) Northwestern University
(Northwestern series); (v) Rush Alzheimer’s Disease Center
(Religious Orders Study and Rush Memory and Aging
Project); (vi) University of California Los Angeles (Small
series); (vii) Instituto de Salud Carlos III, Madrid, Spain
(Spanish series); (viii) University of Toronto Memory Clinic
(Toronto series); (ix) School of Medicine, Yale University
(Turkish series); (x) University of California San Francisco
Memory and Aging Center (UCSF series); and (xi) other cen-
tres (Other series). All individuals gave authorization for gen-
etic testing research in accordance with the local regulations.
Each institution’s Committee on Human Research approved
the study. Clinical diagnoses were rendered by expert neurolo-
gists at each institution. In this study, a diagnosis of FTD de-
notes clinically deﬁned behavioural variant FTD or primary
progressive aphasia. Participants or their surrogates provided
informed consent before participation.
Genetic analysis
Genotypes were obtained using TaqMan SNP assays from
Life Technologies on a LightCycler 480 System. A custom
assay (#AHHR7R6) was designed for MAPT p.A152T
rs143624519. Forward primer sequence was CCAATGGT
GAAAAACCCCTCTATCA and reverse primer sequence was
TTGGCCTGGCCCTTCTG. Reporter sequences were AA
AACGAAGATCACCACACC and ACGAAGATCGCCACA
CC. p.A152T carriers were conﬁrmed using Sanger sequen-
cing. Statistical analysis was performed in R (version 3.1.3,
www.r-project.org).
Zebrafish experiments
Maintenance of stocks and collection of embryos
All zebraﬁsh experiments were performed in accordance with
Home Ofﬁce Guidelines and local ethical committee approval.
Zebraﬁsh were reared under standard conditions on a 14 h
light: 10 h dark cycle. Embryos were collected from natural
spawnings, staged according to established criteria (Kimmel
et al., 1995) and reared in embryo medium (5mM NaCl,
0.17mM KCl, 0.33 mMCaCl2, 0.33mM Mg2SO4, 5mM
HEPES) at 28.5C in the dark. The EIF1::Gal4VP16 line
was made in-house by subcloning the Xenopus EIF1 pro-
moter (Burket et al., 2008) into a 5’ entry cloning vector
(Multisite Gateway technology, ThermoFisher), and recom-
bination was performed according to the manufacturer’s in-
structions using pME-Gal4VP16 and p3E-polyA components
of the Tol2kit (Kwan et al., 2007). The beta-actin::Gal4VP16
line was generated from a transgenic construct comprising
p5E-beta-actin, pME-Gal4-VP16 and p3E-polyA, components
of the Tol2kit, using Gateway recombination (Life
Technologies) into the destination vector pDestTol2CryECFP.
pDestTol2CryECFP was generated by cloning a Cry:ECFP ex-
pression cassette (a kind gift of Michael Parsons) into the des-
tination vector pDestTol2CG2 (Kwan et al., 2007) to replace
the CG2 transgenic marker. The pan-neuronal Gal4 driver line
(hereafter referred to as PanN::Gal4VP16) was a kind gift
from Herwig Baier [identiﬁed as line s1101tEt in the original
publication (Scott et al., 2007)].
Generation and microinjection of
Dendra-tau constructs
Human wild-type and A152T mutant MAPT (2N4R) in
pCDNA3.1 (a gift from Dr Li Gan) were subcloned into
pDendra2 (Adam et al., 2009) at KpnI and ApaI sites. The
Dendra-tau fusion construct was then subcloned into a middle
entry cloning vector (Multisite Gateway technology,
ThermoFisher), and recombination was performed according
to the manufacturer’s instructions using p5E-UAS and p3E-
polyA components of the Tol2kit (Kwan et al., 2007) to gen-
erate the transgenic construct UAS::Dendra-tau-polyA within a
destination vector (pDestTol2CG2). The destination vector
contains a reporter construct [comprising EGFP driven by
the cardiac myosin light chain (CMLC) promoter in the re-
verse orientation to the Dendra-tau transgene] and is ﬂanked
with Tol2 sites to facilitate genomic integration. The resulting
vectors for Dendra-tauWT and Dendra-tauA152T were termed
Responder constructs (Supplementary Fig. 1). Plasmids were
prepared by extraction with a NucleoBond Xtra plasmid
puriﬁcation Kit (Machery Nagel) and subsequent phenol/
chloroform extraction. Tol2 transposase mRNA was synthe-
sized from the Not1-linearized pCS2FA-transposase vector
(Kwan et al., 2007) with the Ambion mMESSAGE
mMACHINE kit (Applied Biosystems) according to the
manufacturer’s instructions.
Responder constructs were mixed with Tol2 transposase
mRNA, at a ﬁnal concentration of 100 ng/ml of DNA and
25 ng/ml of RNA in Danieau’s solution (58mM NaCl,
0.7mM KCl, 0.4mM MgSO4.7H2O, 0.6mM, 5mM HEPES,
pH 7.6) containing 20% phenol red. The freshly prepared
DNA/mRNA was injected into the cell of 1 cell-stage embryos
of the EIF1::Gal4VP16 transgenic line. At 3 days post-fertil-
ization (dpf), embryos were selected for mosaic expression of
Dendra-tau using EGFP ﬁlter sets on an Olympus SZX12
stereo ﬂuorescence microscope then raised to adulthood.
Adult F0 mosaic ﬁsh were outcrossed to TL wild-type ﬁsh
and the F1 generation was screened to identify embryos with
green hearts (EGFP driven from the CMLC::EGFP reporter) to
identify germ line transmitting founders without
EIF1::Gal4VP16 background. These embryos were raised to
establish responder transgenic lines (Supplementary Fig. 1).
Experimental crosses
The eggs collected from a single cross at a single time are gen-
erically termed as a clutch. Crosses with EIF1::Gal4VP16
driver ﬁsh and responder ﬁsh resulted in ubiquitous but
mosaic expression of Dendra-tau, which were used for clearance
assays. Crosses with beta-actin::Gal4VP16 driver ﬁsh and re-
sponder ﬁsh were used for analysis of proteasome function.
Crosses between PanN::Gal4VP16 driver ﬁsh and responder
ﬁsh resulted in Dendra-tau expressed throughout the CNS in
a similar distribution to the expression of endogenous tau (Chen
et al., 2009); such crosses were used for all other experiments
(Supplementary Fig. 1).
Rescue of A152T-tau neurodegeneration via autophagy BRAIN 2016: Page 3 of 19 | 3
Fluorescence and immunofluorescence microscopy
Whole-mount antibody staining was performed according to
standard methods (Schulte-Merker, 2002) using the following
concentrations of antibodies: 1:100 mouse anti-AT8 (Pierce,
Thermo Scientiﬁc); 1:500 mouse anti--acetylated tubulin anti-
body (Sigma-Aldrich); Alexa Fluor 568 (Invitrogen). Samples
for phosphorylation analysis were mounted in 3% methyl cel-
lulose and imaged using a Zeiss Axio Zoom.V16 microscope
with Apotome system. Images comparing two groups of ﬁsh
were performed at the same time using identical settings.
Antibody staining for alpha-acetylated tubulin was performed
on ﬁsh at 3 dpf to quantify abnormalities in motor neuron
length and bifurcation (n = 18 ﬁsh/group) as explained in
Fig. 2B using a GX Optical LED ﬂuorescent microscope,
GXCAM3.3 digital camera and GX Capture software.
Antibody staining of cryosections was performed to detect
phosphorylated tau at residues Thr181 (AT270, 1:50; Pierce,
Thermo Scientiﬁc), Ser202/Thr205 (AT8; 1:50; Pierce, Thermo
Scientiﬁc) and Ser396/Ser404 (PHF1, 1:100; a kind gift from
Dr Peter Davies, Albert Einstein College of Medicine of
Yeshiva University, NY); the conformational tau marker
MC1 (1:50; a kind gift from Dr Peter Davies, Albert
Einstein College of Medicine of Yeshiva University, NY);
and cholinergic neurons (anti-ChAT, 1:125, goat polyclonal
anti-ChAT antibody from Chemicon International). Ten
micrometre cryosections were cut using a Bright cryostat, incu-
bated in 2% H2O2/phosphate-buffered saline (PBS) for 20min
to reduce background staining, blocked in 10% normal goat
or donkey serum (NGS, NDS respectively) in PBS 0.1%
Tween-20 (PBST) for 1 h at room temperature and incubated
with primary antibody in PBST with 0.2% Tween-20 and
10% NGS or NDS overnight at 4C (for 2 days in case of
ChAT detection). Sections were washed, incubated with Alexa
Fluor 568 secondary antibodies then washed and mounted
using VECTASHIELD HardSet with DAPI (Vectorlabs) and
visualized using a Zeiss Axio Zoom.V16 microscope.
Cholinergic neuron number was quantiﬁed from transverse
sections of spinal cord of larvae at 6 dpf. The number of
ChAT-positive motor neurons was quantiﬁed manually
across 20 sections of the spinal cord from the dorsal ﬁn
region (n = 5 ﬁsh/group).
Phenotypic analysis was performed using ﬂuorescence and
brightﬁeld microscopy on a Zeiss Axio Zoom.V16 microscope.
Intensity of ﬂuorescence in whole ﬁsh was analysed using the
‘ROI manager’ tool in ImageJ software. Analysis of axonal
defects was performed on live transgenic larvae at 3 dpf.
Larvae were anaesthetized with tricaine, ﬂat mounted in 1%
low melting agarose in embryo medium and viewed using a
Leica SP2 laser confocal microscope using a 20  objective
and ‘z-stack’ tool. Images were then processed with FIJI soft-
ware (ImageJ) with maximum projections of z-stacks with con-
stant stack height containing the whole neuronal projection.
RNA preparation and quantitative reverse tran-
scription polymerase chain reaction
Pools as well as individual embryos from independent clutches
of WT-tau and A152T-tau ﬁsh crossed to driver
PanN::Gal4VP16 ﬁsh were collected at 24 hours post-fertiliza-
tion (hpf) (pre-phenotype) and 3 dpf (post-phenotype). Some
siblings from each clutch were set aside and kept for subse-
quent quantiﬁcation of phenotypic defects at 3 dpf (post-
phenotype). Total RNA from a pool of n = 10 ﬁsh from the
same clutch or from single ﬁsh was isolated using RNeasy-Plus
Mini-Kit (Qiagen) according to manufacturer’s instructions.
A total of 50 ng of RNA from pools of ﬁsh and 10 ng from
individual ﬁsh was then used in One-Step qRT-PCR combining
cDNA synthesis by speciﬁc-primed reverse transcription and
real-time PCR reaction according to manufacturer protocols
(Invitrogen) using TaqMan Enzyme mix and customized
TaqMan gene-speciﬁc primers for Gal4, Dendra and
GAPDH as housekeeping gene (GAPDH TaqMan made-to-
order gene expression code 4351372 Dr03436845_g1 from
Applied Biosystem; Gal4_F GCTCAAGTGCTCCAAAGAA
AAACC and GAL4_R CGACACTCCCAGTTGTTCTTCA;
Dendra_F ACAAGGGCATCTGCACCAT and Dendra_R
AAGCGCACGTTCTGGAAGA). All samples were run in trip-
licate and were analysed on a StepOne Plus Real Time PCR
System and StepOneTM Sofware V.2.1 (Applied Biosystems,
Life Technologies). Relative gene expression was normalized
to GAPDH controls and assessed using the 2CT method.
Western blotting
Fish were collected and lysed on ice with lysis buffer contain-
ing 1% octylglucoside, complete protease inhibitor cocktail
and PhosSTOP
TM
tablets (Sigma). Fish were homogenized by
sonication and lysates were centrifuged at 7000 rpm for 1min
at 4C. Supernatants were diluted in 2  Laemmli Buffer at a
1:1 dilution, resolved by sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (12% and 16% gels) and transferred
to PVDF membranes. The membranes were blocked with PBST
containing 5% non-fat dry milk and were then incubated over-
night at 4C with primary antibodies diluted in PBST.
Membranes were washed three times in PBST, incubated for
1 h at room temperature with 1:5000 dilution of horseradish
peroxidase-conjugated secondary anti-mouse or anti-rabbit
antibodies (Dako) in PBST, and washed three times for
10min each. Immunoreactive bands were then detected using
ECL
TM
(GE Healthcare Bioscience). Quantiﬁcation of proteins
normalized to actin, GAPDH or Dendra was performed using
ImageJ (FIJI) software. The following antibodies were used:
mouse anti-Actin (1:1000; Sigma-Aldrich), mouse anti-
GAPDH (1:1000; Millipore), rabbit anti-Dendra (1:1000;
Online Antibodies), Tau5 mouse anti-tau (1:1000; Abcam),
mouse anti-AT270 (1:1000; Pierce, Thermo Scientiﬁc), mouse
anti-AT8 (1:200; Pierce, Thermo Scientiﬁc), mouse anti-PHF1
(1:100; a kind gift from Dr Peter Davies, Albert Einstein
College of Medicine of Yeshiva University, NY) rabbit anti-
body against cleaved (activated) caspase 3 (1:100; Abcam),
rabbit anti-Atg5 antibody (1:1000; Abcam) and rabbit anti-
LC3 antibody (1:1000; Novus Biologicals) mouse anti-1-7
subunits of the proteasome 20S (1:1000; Enzo), mouse anti-
P4D1 antibody for ubiquitinated proteins (1:1000, Cell
Signalling), rabbit anti-GFP antibody (1:1000, Abcam).
TUNEL
Terminal deoxynucleotidyl transferase dUTP nick end labelling
(TUNEL) assay was performed using an In Situ Cell Death
detection kit (Fluorescein or TMR; Roche Diagnostics). Ten
micrometre transverse or longitudinal cryosections were ﬁxed
in 4% paraformaldehyde at room temperature for 15min and
permeabilized with 20 mg/ml proteinase K. A slide treated with
DNase (4 U/200 ml; Ambion) was used as positive control.
TUNEL was performed according to the manufacturer’s
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instructions and sections were mounted with VECTASHIELD
Hard Set containing DAPI (Vectorlabs). Digital images were
captured using GX Optical LED ﬂuorescent microscope and
GXCAM3.3 digital camera using GX Capture software
(Version 6.2.3.0). Longitudinal sections of Dendra-tau ﬁsh
from 24 hpf to 5 dpf were used in a ﬁrst approach to deter-
mine a suitable time-point for the quantiﬁcation of cell death.
Transverse sections through the brain of 2 dpf and 6 dpf
zebraﬁsh larvae were used to quantify the number of apoptotic
neurons. The mean number of TUNEL-positive nuclei was
calculated for each genotype and phenotype (n = 5 ﬁsh) from
a minimum of ﬁve sections across the brain and eyes per ﬁsh.
Isolation of soluble and sarkosyl-insoluble tau
fractions
Fractionation and analysis of soluble and insoluble tau was
performed as previously described (Santacruz et al., 2005)
with minor modiﬁcations. WT-tau and A152T-tau ﬁsh were
collected dry at 24 hpf and 3 dpf and stored at 80C (55 ﬁsh
collected per independent sample, corresponding to 18mg).
Frozen samples were homogenized by addition of 10 v/w ice-
cold Tris-buffered saline (TBS: 25mM Tris pH 7.4, 150mM
NaCl, 1mM EDTA, 1mM EGTA) supplemented with
Protease Inhibitor Cocktail, 1mM PMSF, phosphatase inhibi-
tor cocktail II and III (all Sigma) and disrupted using glass
beads in a Tissuelyser LT (Qiagen). Sample homogenate
(150ml) was ultracentrifuged at 150 000 g for 15min at 4C.
Supernatant was collected (soluble tau fraction) and protein
quantiﬁcation performed. The pellet was re-homogenized in
150ml high salt/sucrose buffer (10mM Tris pH7.4, 0.8M
NaCl, 10% Sucrose, 1mM EGTA, 1mM PMSF) and ultracen-
tifuged as before. Supernatant was incubated with a ﬁnal
volume of 1% sarkosyl for 1 h at 37C before ultracentrifuga-
tion at 150 000 g for 1 h at 4C. The pellet (sarkosyl-insoluble
tau) was resuspended directly in 30 ml of Laemmli buffer and
boiled at 100C for 5min. Western blots were performed as
previously described using soluble and sarkosyl-insoluble tau
samples run on 10% tris-glycine gels. Blots were blocked in
5% non-fat milk in PBST and incubated with primary anti-
bodies Tau-5 (1:1000, Abcam) and actin (1:1000 Sigma-
Aldrich).
Thioflavin-S staining
Modiﬁed Thioﬂavin-S staining (Guntern et al., 1992) was per-
formed on transverse cryosections of 6 dpf larvae at the pos-
ition of the optic chiasm. The sections were pretreated in
potassium permanganate solution for 4min followed by
bleach treatment, then rinsed in water and incubated in
0.1% Thioﬂavin-S in 50% ethanol for 5min at room tempera-
ture in the dark. Sections were brieﬂy differentiated in 50%
ethanol solution, rinsed in water then mounted using
VECTASHIELD Hard Set with DAPI. Sections were exam-
ined using a Zeiss Axioplan2 ﬂuorescent microscope equipped
with a QImaging Retiga 2000 R digital camera.
Quantification of Dendra-tau clearance
Crosses of UAS::Dendra-tau responder ﬁsh with EIF1::Gal4VP16
driver ﬁsh were performed to produce offspring with ubiquitous
but mosaic expression of the transgene to allow visualization of
individual neurons in the spinal cord. Embryos were sorted at
24 hpf to identify ﬂuorescent Dendra-tau expressing
individuals. Photoconversion of individual spinal cord neu-
rons was performed on 2 dpf larvae anaesthetized by immer-
sion in 0.2mg/ml 3-amino benzoic acid ethyl ester (MS222)
and mounted in 1% low melting agarose in embryo medium.
Photoconversion of Dendra, previously described to track
protein dynamics (Chudakov et al., 2007), was performed
by UV irradiation (405 nm) for 3 s using Bleachpoint tool
and a confocal microscope Leica SP8 at 3 magniﬁcation
with 40 objective. Digital ﬂuorescent images of individual
neurons in larvae with Dendra-tau mosaic expression were
taken immediately after photoconversion and at 12-h inter-
vals over a further 48 h. The images were then analysed using
ImageJ by selecting regions of interest around each neuron
with Dendra-tau expression and ﬂuorescent intensity was
measured using ‘ROI’ and ‘Integrated Density’ functions. To
monitor Dendra-tau clearance the ﬂuorescent intensity of
each cell was quantiﬁed at each time point and expressed
as a percentage of the initial ﬂuorescent intensity, immedi-
ately after photoconversion.
Compound treatment in Dendra-tau fish
Dendra-tau embryos were reared in embryo medium until 24
hpf then treated with either 0.1% dimethyl sulphoxide
(DMSO), 30 mM rapamycin, 50 mM rilmenidine or 30 mM clo-
nidine from 24 hpf to 3 dpf with drugs and medium replen-
ished daily. The percentage of larvae with different phenotypes
was quantiﬁed at 3 dpf. Phenotypes were classiﬁed either as
normal; mild (when slight torsion of dorsal spine was
observed); moderate (when head axis was not aligned to the
dorsal spine but the larvae could swim straight); and severe
(when ﬁsh showed a complete torsion of whole body in ‘U’-
shape). To analyse the clearance of Dendra-tau in presence of
modulators of autophagy or proteasome function, ﬁsh were
reared in conventional embryo medium until the moment of
photoconversion at 48 hpf and immediately after treated with
0.1% DMSO, 30 mM clonidine, 30 mM rapamycin, 50 mM
rilmenidine, 10mM NH4Cl or 100 mM MG132, also refreshed
daily.
Behavioural assays
Zebraﬁsh larvae (72 hpf and 6 dpf) from independent clutches
were sorted for ﬂuorescent Dendra-tau expression and tested
individually. The WT-tau and A152T-tau ﬁsh were compared
to negative (non-ﬂuorescent) siblings. Motility was analysed by
tapping the dish containing a single ﬁsh to induce the escape
response. The gentle tap was repeated three times with a rest
time of 15 s inbetween to avoid habituation. Only the move-
ments involving motion to a different position were considered
an escape response. Three replicate experiments were per-
formed with a minimum of 20 ﬁsh per genotype per experi-
ment using larvae from independent clutches for each replicate.
Atg5 injection
A middle entry clone vector (Multisite Gateway technology,
ThermoFisher) containing Zebraﬁsh atg5 was generated after
adding a 5’ attB1 site followed by a FLAG tag and a 3’ attB2
site by PCR (attB1FLAGatg5fow 5’-GGGGACAAGTTTGTAC
AAAAAAGCAGGCTCAATGGACTACAAAGACGATGACG-
ACAAGATGATAATGGCAGATGACAAG-3’ attB2atg5rev
5’-GGGGACCACTTTGTACAAGAAAGCTGGGTAGAGAG-
CGGGAGGGTTAATGT-3’) using an atg5 cDNA clone
(Source Bioscience, MGC 100934, IMAGE:7145909) as
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template. Recombination of the PCR product and the
pDONR221 vector clone was performed according to the
manufacturer’s instructions. The transgenic construct
UAS::FLAGatg5-polyA was generated using the
pME_FLAGatg5 vector together with p5E-UAS and p3E-
polyA components of the Tol2 kit within a destination
vector (pDestTol2CG2) (Kwan et al., 2007). The destination
vector contains a reporter construct (comprising EGFP driven
by the CMLC promoter in the reverse orientation to the atg5
transgene) and is ﬂanked with Tol2 sites to facilitate genomic
integration.
The UAS construct containing atg5 was co-injected with
Tol2 transposase mRNA (25 ng/ml of DNA and 25 ng/ml of
RNA in Danieau’s solution containing 20% phenol red) into
the cell of 1 cell-stage embryos from the cross of A152T-tau
responder ﬁsh with PanN::Gal4VP16 driver ﬁsh. At 2 dpf,
injected embryos and non-injected siblings expressing
Dendra-tau were analysed to quantify the proportion of
phenotypes, then collected for western blotting as previously
described.
Proteasome function assay
Dendra-tau positive larvae (48 hpf) from at least six independ-
ent clutches of PanN::Gal4VP16 crossed with responder ﬁsh
were homogenized in 50mM Tris (pH 7.5), 1mM DTT by
brief sonication (twice for 10 s) and each clutch was analysed
in triplicate for control (1% DMSO) and MG132 (1.5 mM)
treatments. Tissue lysates were centrifuged at 16 900 g for
10min at 4C, protein concentration determined using a ﬂuor-
escence-based quantitation assay kit (Qubit, ThermoFisher
Scientiﬁc). Samples normalized for protein concentration
(20 mg total amount of protein) were loaded in a 96-well-
plate. Chymotrypsin-like activity of the 26S proteasome was
monitored using a FLUOstar Omega ﬂuorometer (BMG
Labtech) with Omega.LNK software. The reaction started by
the addition 100mM Suc-LLVY-AMC (Enzo) diluted in homo-
genizing buffer (‘time zero’). The activity was assayed by mea-
suring the ﬂuorescence intensity during 3 h at 37C, in 5-min
intervals (excitation 355 nm; emission 460 nm). Samples of the
same lysates were also loaded on a 16% non-denaturing gel
for western blot analysis to detect proteasome 20S core par-
ticle levels using the anti-1-7 antibody.
UbG76V-GFP injections
The proteasome reporter UbG76V-GFP in pEGFP-N1 [kindly
provided by N. Dantuma (Dantuma et al., 2000)] was sub-
cloned into a middle entry cloning vector (Multisite Gateway
technology, ThermoFisher) at NheI and NotI sites and recom-
bination was performed with p5E-UAS and p3E-polyA into
pDestTol2CG2 (components of the Tol2kit; Kwan et al.,
2007) to generate the UAS::UbG76V-GFP reporter construct
ﬂanked with Tol2 sites to facilitate genomic integration. The
UAS::UbG76V-GFP reporter construct was co-injected with the
Tol2 transposase mRNA (25 ng/ml of DNA and 25 ng/ml of
mRNA in Danieau’s solution containing 20% phenol red)
into the cell of one cell-stage embryos from the cross of
A152T-tau responder ﬁsh with beta-actin::Gal4VP16 driver
ﬁsh. At 24 hpf embryos were selected for Dendra-tau expres-
sion and treated either with DMSO or 100 mM MG132. After
8 h of treatment, ﬁsh were anaesthetized and collected for
western blotting as described previously.
Statistics
Mean values, standard error of the mean (SEM) and standard
deviations were calculated with Microsoft Excel. Statistical
analysis was performed using two-tailed Student’s t-test or
Student-Newman-Keuls one-way ANOVA in GraphPad
InStat 3. Data are presented as mean  SEM or standard de-
viation (SD). P5 0.05 was considered signiﬁcant.
Results
p.A152T shows significantly higher
risk for progressive supranuclear
palsy syndrome and frontotemporal
dementia
Among 3100 patients with neurodegenerative disease, we
identiﬁed 23 p.A152T carriers (Fig. 1): one carrier in 133
cases with corticobasal syndrome (0.75%); two carriers in
462 cases with mild cognitive impairment (0.43%); ﬁve
carriers in 927 cases with Alzheimer’s disease (0.54%);
seven carriers in 913 FTD cases (0.77%); and eight in
435 cases with PSP-S (1.84%). No carrier was identiﬁed
among our cohorts of amyotrophic lateral sclerosis
(n = 24) and Parkinson’s disease (n = 206) individuals.
Ten in 4351 control individuals carried the p.A152T
allele (0.23%). This frequency is similar to the one
observed in over 60 000 unrelated individuals from the
Exome Aggregation Consortium (ExAC, http://exac.broad-
institute.org/), with 159 carriers (three of them homozy-
gous) among 60 472 individuals (0.26%). Demographic
characteristics of this replication cohort are described in
Supplementary Table 1.
A combined analysis performed on the 3100 patients
placed the estimated OR at 3.24 (CI: 1.48–7.65, Fisher’s
exact test, P = 0.0013) for overall neurodegenerative dis-
eases versus controls. Analyses on the different individual
disease cohorts, revealed OR ranging between 1.89 (in the
MCI cohort) and 8.13 (in the PSP-S cohort) (Fig. 1).
However, the association was only signiﬁcant for the
PSP-S (OR = 8.13, CI: 2.77–22.99, Fisher’s exact test,
P = 8.43  105) cohort and nominally signiﬁcant for the
FTD (OR = 3.35, CI: 1.08–9.79, Fisher’s exact test,
P = 0.0180) cohort. As this is a targeted replication study
aiming to test a single variant, these P-values are sufﬁcient
support for the hypothesis, as they do not require correc-
tion for testing of multiple loci.
A152T-tau zebrafish show abnormal
phenotypes and motility defects
To test the functional consequences of the A152T variant
in vivo, we generated new zebraﬁsh models exploiting the
Gal4-UAS binary expression system (Halpern et al., 2008).
We used responder constructs comprising wild-type or
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mutant A152T human tau (2N4R) fused to the sequence
encoding the photoactivatable protein Dendra (Adam et al.,
2009), downstream of UAS. Dendra-tau expression was
driven either ubiquitously using EIF1::GAL4-VP16 or
beta-actin::Gal4VP16, or throughout the nervous system
using pan-neuronal::GAL4-VP16 (PanN::Gal4VP16) dri-
vers (Supplementary Fig. 1A–C). Pan-neuronal expression
of the wild-type tau transgene (WT-tau) caused no obvious
morphological defects, whereas ﬁsh expressing A152T
mutant tau (A152T-tau) showed abnormal phenotypes in
50% of the clutch, the most signiﬁcant feature being ab-
normal curvature of the dorsal spine (Fig. 2A). Analysis of
the motor neurons revealed no abnormalities in the WT-tau
transgenic ﬁsh, while pathﬁnding and branching defects
were observed in A152T-tau ﬁsh, notably even in ﬁsh
with normal gross morphology (Fig. 2B and C and
Supplementary Fig. 2A). In addition, the motor neuron
population in the spinal cord was markedly reduced in
A152T-tau at ﬁsh at 6 dpf (Supplementary Fig. 2B and
C). In accordance with these neuronal defects, A152T-tau
larvae had impaired escape responses to stimuli (Fig. 2D
and Supplementary Fig. 2D).
Wild-type and mutant transgenes are
expressed at similar levels but tau
protein levels are increased in
A152T-tau fish
As morphological and behavioural defects were only
observed in A152T-tau ﬁsh, we next assessed whether
this was a consequence of different levels of transgene ex-
pression. At 3 dpf, Dendra-tau protein was observed to be
signiﬁcantly higher in A152T-tau ﬁsh compared to those
expressing the WT-tau (Fig. 2E). We conﬁrmed that this
was speciﬁcally expression of the Dendra-tau fusion protein
as the same band could be detected with both Dendra and
Tau5 antibodies (the latter raised against human tau
protein; Fig. 2F and Supplementary Fig. 4D). However,
we also observed that the ﬂuorescent Dendra signal
(which is a surrogate for tau protein levels, as this is a
fusion protein), was not different between the two trans-
genic lines at the onset of transgene expression at 24 hpf
(Supplementary Fig. 3A). Similarly, when larvae were se-
lected for similar expression levels of Dendra ﬂuorescence
at 24 hpf (pre-phenotype), ﬁsh expressing the WT-tau
transgene developed normally, whereas those expressing
the A152T-tau transgene developed spinal curvature defects
by 3 dpf (Supplementary Fig. 3B). To deﬁnitively address
whether the WT-tau and A152T-tau transgenes were ex-
pressed at similar levels, we measured mRNA levels by
quantitative RT-PCR on clutches from WT-tau and
A152T-tau ﬁsh at 24 hpf (pre-phenotype) and correlated
this with the distribution of morphological phenotypes pre-
sent in the same clutches at 3 dpf (Fig. 2G, Supplementary
Fig. 4A–C). Notwithstanding the variability found in the
levels of expression of both Gal4 and Dendra-tau in differ-
ent clutches, high levels of Dendra-tau mRNA expression
were observed in WT-tau ﬁsh that always displayed a
normal phenotype, whereas lower levels of Dendra-tau
mRNA expression at 24 hpf (pre-phenotype) in A152T-
tau ﬁsh resulted in subsequent phenotypic abnormalities
at 3 dpf (Supplementary Fig. 4C). This was further veriﬁed
by identifying clutches of ﬁsh having equivalent levels of
Dendra-tau mRNA at 24 hpf [clutches 2 and 5, Fig. 2G(i)]
and, as previously observed, only those expressing the
A152T-tau transgene developed morphological abnormal-
ities [Fig. 2G(ii)]. When mRNA expression levels were mea-
sured in individual ﬁsh, we observed no difference in
transgene expression at 24 hpf. Similarly, at 3 dpf, no dif-
ferences in mRNA expression levels were observed between
ﬁsh expressing WT-tau and ﬁsh expressing A152T-tau with
moderate and severe phenotypes. Interestingly, we observed
signiﬁcantly lower expression levels in morphologically
normal A152T-tau ﬁsh and this is likely to account for the
lack of defects observed in these individuals (Fig. 2H).
Figure 1 MAPT p.A152T carrier frequencies and associated odds ratio for the different disease cohorts. The total number of
individuals and p.A152T carriers for each of the disease cohorts and controls is shown in the table (left), with odds ratios and nominal P-values
depicted in the forest plot (right). Overall refers to the combined neurological disease patient samples. In the forest plot, squares represent the
estimate odds ratio and are drawn proportional to the weight of the sample and lines represent 95% confidence intervals.
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Figure 2 Phenotypic characterization of Dendra-tau transgenic zebrafish. (A) Representative images of fish with pan-neuronal
expression of WT-tau and A152T-tau. In all clutches of WT-tau offspring, larvae were normal. In contrast, A152T-tau fish showed abnormal
phenotypes in 50% of each clutch. Differing degrees of abnormal curvature of the dorsal spine was observed in A152T-tau fish (percentages
refer to the number of the larvae within each severity range per clutch; observations based on more than 30 individual clutches per transgenic
line). Scale bar = 1 mm. (B) Motor neuron morphology was analysed by confocal microscopy on live fish and abnormalities found only in A152T-
tau fish including truncation, abnormal pathfinding and aberrant branching (ramifications) (i) WT-tau; (ii–iv) A152T-tau, with normal (ii), moderate
(iii) and severe (iv) phenotypes. (v) Schematic view of a single somatic motor neuron (mn) unit from the spinal cord (sc) to the yolk extension (ye)
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Together, these ﬁndings conﬁrmed that the defects observed
in A152T-tau ﬁsh were not a consequence of higher mRNA
expression levels but are speciﬁc to the mutant (A152T)
form of the tau protein.
A152T-tau zebrafish show increased
tau-associated pathology
We next investigated the two transgenic lines for evidence
of tau-associated pathology. Pathological hyperphosphory-
lation of tau is a hallmark of tauopathies (Iqbal et al.,
2010). Both transgenic WT-tau and A152T-tau ﬁsh
showed positive staining for the hyperphosphorylation
markers AT270 (residue Thr181), AT8 (residues Ser202/
Thr205) and PHF1 (residues Ser396/Ser404) by whole-
mount immunostaining (Fig. 3A and Supplementary Fig.
5). By western blotting, we observed that phosphorylation
at multiple sites was increased in the A152T-tau ﬁsh rela-
tive to total protein (actin) levels and total tau (Dendra)
levels (Fig. 3B and C). To determine whether transgene
expression resulted in the formation of tau aggregates, we
performed analysis of soluble and sarkosyl-insoluble tau.
An abundance of sarkosyl insoluble tau was observed
only in samples from A152T-tau ﬁsh (Fig. 4A). In addition,
positive MC1 antibody staining, a marker of tau conform-
ational change, was detected only in A152T-tau samples at
6 dpf and not in WT-tau transgenic ﬁsh (Fig. 4B). We also
observed thioﬂavin-S staining, a well-established staining
technique for neuroﬁbrillary tangles (Guntern et al.,
1992), which are a characteristic of tau pathology, to be
more abundant in the A152T-tau ﬁsh (Supplementary Fig.
6). Likewise, the levels of activated caspase 3, a marker for
apoptosis (Fig. 4C), and number of apoptotic cells were
increased in the A152T-tau zebraﬁsh, and correlated with
the morphological abnormalities (Fig. 4D and E and
Supplementary Fig. 7). Together, these results demonstrate
that A152T-tau expression is associated with greater tau-
associated pathology and neurodegeneration.
Delayed clearance of A152T-tau is
associated with defects in
proteasome function but not
autophagy
To study the inﬂuence of the A152T variant on tau turn-
over rate, we expressed Dendra-tau under the control of
mosaic ubiquitous EIF1::Gal4VP16 driver, as the mosaic
expression enables analyses in single cells. Quantiﬁcation of
Dendra, a green-to-red photoconvertible ﬂuorescent protein
fused to tau, enabled assessment of tau clearance kinetics in
individual spinal cord motor neurons in vivo. Mosaic ﬁsh
were imaged before and after photoconversion then at
deﬁned intervals thereafter, to assess clearance of the red,
photoconverted, ﬂuorescently-tagged tau protein
(Supplementary Fig. 8). Interestingly, A152T-tau showed
signiﬁcantly slower clearance kinetics than the WT-tau
in vivo (Fig. 5A and B). As tau protein is known to be a
substrate for both the proteasome and for autophagic
Figure 2 Continued
and its ramifications divided into dorsal (arrowhead 1) and medial (arrowhead 2). Arrowhead 3 labels normal axonal length reaching the yolk
extension. Panels vi–x correspond to magnified images of i–iv highlighting normal (white arrowheads) or abnormal (black arrowheads) ramifi-
cations and length according to axonal scheme represented in v [vi corresponds to WT-tau (i); vii corresponds to normal phenotype A152T-tau
(ii); viii corresponds to moderate phenotype A152T-tau (iii); ix and x correspond to severe phenotype A152T-tau (iv)]. Scale bar = 50mm. See
also Supplementary Fig. 2. (C) Quantification of the branching defects observed in motor neurons (MN) according to scheme in B(v) at 3 dpf.
Abnormalities at any specified point (arrowheads 1, 2 or 3) were counted as abnormal (five segmental motor neuron units within the yolk sac
extension region of the trunk, anterior to the urogenic opening, were counted for n = 18 fish per group; graph represents mean  SD; two-tailed
t-test, P5 0.01 and P5 0.001 versus WT-tau). (D) Escape response defects were observed in A152T-tau but not WT-tau fish at 6 dpf (three
independent experiments in triplicate, n = 20/group shown as mean  standard error; P5 0.001 versus negative siblings by two-tailed t-test).
(E) Fish expressing A152T-tau show significantly higher levels of total human tau protein at 3 dpf (mean  SEM, n = 3 independent clutches in
triplicate, P5 0.001 versus WT-tau by two-tailed t-test). (F) Levels of Dendra-tau protein (120 kDa) could be equally detected by western
blot with either Dendra or Tau5 antibodies (mean  standard error of four clutches in triplicate, by two-tailed t-test). (G) The higher levels of
Dendra-tau together with the morphological and motility defects observed in A152T-tau fish are not the result of higher levels of expression of
the transgene (mRNA levels). [G(i)] Quantification of the mRNA expression levels of Dendra and Gal4 by quantitative RT-PCR at 24 hpf (pre-
phenotype) shows variability in the expression of Dendra between different clutches of WT-tau fish (three independent clutches labelled 1–3) and
A152T-tau fish (three independent clutches labelled 4–6). Analysis was performed on groups containing n = 10 fish. [G(ii)] Phenotypic assessment
of larvae at 3.dpf from the same clutches analysed in [G(i)] shows abnormal phenotypes in all clutches of A152T-tau fish regardless of the
expression level of Dendra-tau. The similar levels of expression of Dendra in clutches 2 (WT-tau) and 5 (A152T-tau) at 24 hpf resulted in abnormal
phenotypes only in A152T-tau expressing fish (sev = severe, mod = moderate, according to morphological phenotype score presented in A). (H)
Quantification of the mRNA expression levels of Dendra and Gal4 from 10 individual fish collected from clutches 2 (WT-tau) and 5 (A152T-tau).
When siblings from these clutches were analysed as pooled samples, equal Dendra mRNA expression levels were observed at 24 hpf. When
mRNA expression levels of Dendra or Gal4 were measured in single WT-tau and A152T-tau fish at 24 hpf (pre-phenotype), no significant
differences were observed. [H(i)]. At 3 dpf [H(ii)] WT-tau and A152T-tau individual fish with moderate and severe phenotypes had equivalent
levels of Dendra and Gal4 mRNA expression. However, A152T-tau fish which were morphologically normal were found to have significantly lower
levels of Dendra mRNA expression [H(ii)].
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Figure 3 Phosphorylation state of tau in Dendra-tau transgenic zebrafish. Pathological hyperphosphorylation and conformational
changes are hallmarks of tauopathies. (A) Both WT- and A152T-tau expressing larvae showed positive immunostaining for the
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degradation (Berger et al., 2006), the slower clearance of
A152T-tau may be the result of defects in either of these
processes. However, autophagy appeared to be normal in
WT-tau and A152T-tau ﬁsh as we observed no difference
in levels of LC3-II, a well-characterized marker of autop-
hagosome number, either in the presence or absence of
ammonium chloride (Fig. 5C–F). Furthermore, when
clearance experiments were performed in the presence of
ammonium chloride, the rate of clearance was slowed to
the same extent in both WT-tau and A152T-tau ﬁsh, sug-
gesting that autophagy is functioning normally (Fig. 5G
and H).
However, treatment with the proteasome inhibitor
MG132 resulted in different effects on the clearance kin-
etics of WT-tau and A152T-tau ﬁsh. While MG132 treat-
ment slowed the clearance of WT-tau (Fig. 6A), it had no
effect on the clearance of A152T-tau, suggesting that pro-
teasome activity may be suppressed in ﬁsh expressing the
A152T variant (Fig. 6B). To investigate this further, we
measured proteasome activity using a synthetic proteasome
substrate and found signiﬁcantly reduced activity in the
A152T-tau ﬁsh lysates compared to those from WT-tau
ﬁsh (Fig. 6C). This is likely a result of reduced proteasome
function, as a structural component of the proteasome was
equally abundant in both transgenic lines (Fig. 6D and E).
To investigate proteasome activity in vivo, we used transi-
ent expression of UbG76V-GFP (Dantuma et al., 2000) in
ﬁsh with ubiquitous expression of WT-tau or A152T-tau.
The presence of the ubiquitin sequence linked to GFP tar-
gets the ﬂuorescent protein for rapid degradation by the
proteasome under normal conditions, however, when pro-
teasome function is perturbed then GFP is detected. In non-
transgenic ﬁsh, the GFP signal is barely detected under
basal conditions but was evident in the presence of
MG132, with similar effects observed in WT-tau ﬁsh.
However, in A152T-tau ﬁsh, the basal level of GFP
was higher than that of non-transgenic and WT-tau ﬁsh
(Fig. 6F and G) suggesting that the proteasome is impaired
in these ﬁsh. In addition, levels of endogenous ubiquiti-
nated proteins were higher in A152T-tau ﬁsh compared
to WT-tau ﬁsh, and treatment with MG132 failed to in-
crease the levels of ubiquitin-conjugated proteins further
(Fig. 6H and I), suggesting that there was accumulation
of proteins which are predominantly substrates of the
proteasome.
Delayed clearance of A152T-tau is
associated with pathology and can be
ameliorated by enhancing autophagy
As (macro)autophagy induction can enhance the clearance
of tau (Berger et al., 2006; Moreau et al., 2014) and autop-
hagic ﬂux was normal in our transgenic zebraﬁsh (Fig. 5C–
H), we tested the effects of clonidine, rilmenidine and rapa-
mycin, known autophagy inducers (Williams et al., 2008),
on the clearance of A152T-tau. This pharmacological
autophagy upregulation enhanced the clearance of
A152T-tau (Fig. 7A and B), rescued the morphological
abnormalities of the ﬁsh (Fig. 7C and D) and ameliorated
the motility defects (Fig. 7E). Furthermore, autophagy upre-
gulation also resulted in a reduction in hyperphosphory-
lated tau (Fig. 7F and G) and in lower activated caspase3
levels in treated versus untreated A152T-tau ﬁsh (Fig. 7H
and I).
To further validate that upregulation of autophagy ame-
liorated defects in A152T-tau ﬁsh, we used a genetic ap-
proach using transient over-expression of the key
autophagy gene atg5. Injection of an expression vector
encoding zebraﬁsh Atg5 into A152T-tau ﬁsh at the one
cell stage resulted in over-expression of Atg5 protein at 2
dpf (Fig. 7J and K). The increase in Atg5 protein correlated
with increase in LC3-II, a well-characterized reporter for
autophagosome number, demonstrating that autophagy
was upregulated in Atg5-injected ﬁsh (Fig. 7J and L).
Phenotypic analysis of Atg5-injected and control (unin-
jected) siblings demonstrated that increased autophagy
was associated with a reduction in the number of offspring
with morphological defects (Fig. 7M and N).
Discussion
Conﬁrmation of genetic associations and functional explor-
ation of the biology of rare variants will be become increas-
ingly important as the scientiﬁc community seeks to utilize
genetic data. Here, we have focused on the p.A152T
MAPT variant. After the initial study that reported signiﬁ-
cant risks for p.A152T carriers to develop Alzheimer’s dis-
ease and FTD spectrum disorders (Coppola et al., 2012),
Labbe et al. (2015) reported signiﬁcant associations with
Figure 3 Continued
hyperphosphorylation markers AT270 (residue Thr181), AT8 (residues Ser202/Thr205) and PHF1 (residues Ser396/Ser404) in cryosections, from
24 hpf onwards. [A(i)] Schematic overview, DAPI and Dendra images of transverse sections through the spinal cord used for phosphorylated tau
detection at 24 hpf (SC = spinal cord, n = notochord, m = muscle block and Y = yolk sac). Scale bar = 50mm. [A(ii)] Fluorescent images of
Dendra-tau (green) and phospho-tau antibodies (red) show positive single neurons stained for AT270, AT8 and PHF1 within the spinal cord in
both WT-tau and A152T-tau fish at 24 hpf. Scale bar = 10 mm. See Supplementary Fig. 5. (B) Western blot for phosphorylation markers AT270,
AT8 and PHF1 in whole fish lysates at 3 dpf. The levels of phospho-tau were significantly increased in A152T-tau fish compared to WT-tau fish
relative to the loading control, actin (mean  SEM of 10 independent clutches; two-tailed t-test, P5 0.001 versus WT-tau). (C) The higher
phosphorylation levels were also observed in A152T-tau fish relative to total tau (Dendra-tau) levels (mean  SEM, n = 24 fish/group of 10
independent clutches for PHF1 and eight independent clutches for AT8; two-tailed t-test, P5 0.001 versus WT-tau).
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Figure 4 Tau aggregation and cell death in Dendra-tau transgenic zebrafish. (A) Levels of sarkosyl-soluble and insoluble tau reflect
accumulation of the insoluble form only in A152T-tau fish at 6 dpf. The level of total tau was analysed by immunoblotting using Tau5 antibody (four
independent clutches for WT-tau and A152T-tau). (B) Antibody staining for the conformational marker MC1 in cryosections across the eye of
WT-tau and A152T-tau fish. No staining was observed in either WT-tau or A152T-tau fish at 3 dpf (left), whereas only A152T-tau presented
positive staining for conformational changes at 6 dpf (right). Scale bar = 100 mm. (C) Western blot for active Caspase 3 (Casp3) (quantified below),
indicative of increased cell death in fish expressing the A152T variant (mean  SEM of nine independent clutches; Student-Newman-Keuls one-
way ANOVA, P5 0.01 versus negative, ##P5 0.01 versus WT-tau). (D) The increased cell death in A152T-tau fish was confirmed by quanti-
fication of TUNEL labelling on transverse sections (mean  SD; n = 5 fish, from a minimum of five sections; Student-Newman-Keuls one-way
ANOVA, P5 0.001 versus negative; ###P5 0.001 versus WT-tau). See also Supplementary Fig. 4. (E) Morphologically abnormal A152T-tau fish
showed increased cell death (quantification of TUNEL-positive nuclei) compared to morphologically normal A152T- or WT-tau fish (mean  SD;
Student-Newman-Keuls one-way ANOVA, P5 0.01 and P5 0.001 versus WT-tau). Representative images in Supplementary Fig. 7.
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Figure 5 Tau clearance in vivo and autophagy function. Clearance kinetics of photoconverted Dendra-tau measured in neurons of WT-
tau and AT152T-tau fish. Measurement of the intensity of the red Dendra-tau signal over time reflects the clearance or degradation of tau protein.
(A) Representative images of photoconverted red Dendra-tau signal comparing a single neuron from WT-tau and A152T-tau fish at three different
timepoints: immediately after photoconversion (0 h), 24 h and 48 h after photoconversion. (B) Quantification of red Dendra-tau intensity in
photoconverted neurons in the spinal cord of WT-tau and A152T-Tau transgenic fish (representative images shown in Supplementary Fig. 8C). The
percentage of residual photoconverted red Dendra-tau was measured over 48 h measured at 12-h intervals. Dendra-tagged A152T-tau clears at a
significantly lower rate than WT-tau. (n = 30/group shown as mean  SD; Student-Newman-Keuls one-way ANOVA, P5 0.01 and P5 0.001
versus WT-tau). (C–F) Western blots for LC3-II, a well-characterized marker of autophagosome number, demonstrate that there are no
differences in the levels of this protein between WT-tau and A152T-tau fish either at 24 hpf (pre-phenotype; C and D) or 72 hpf (post-phenotype;
E and F). (E and F) Measurements of LC3-II levels in the presence or absence of ammonium chloride provides a method for measuring autophagic
flux. No differences were observed between the two transgenic lines at 3 dpf, suggesting that autophagy functions normally in both WT-tau and
A152T-tau fish (graph represents mean  SD of four independent clutches per group for E and F and three for C and D; two-tailed t-test). (G and
H) Clearance kinetics of Dendra-tau was measured in the presence or absence of ammonium chloride. Treatment with ammonium chloride
blocks autophagic flux and delays the clearance of both WT-tau and A152T-tau to the same extent, indicating that flux occurs at the same rate in
these two lines (mean  SD, n = 62 neurons/group; Student-Newman-Keuls one-way ANOVA, P5 0.01 and P5 0.001 versus untreated
group). Note in G and H, the ‘WT-tau + NH4Cl’ (denoted by black squares and black dashed line) overlaps with the ‘A152T-tau’ line (denoted by
grey triangles and grey solid line). The graphs in G and H are presented with a different line in the foreground and background to aid
interpretation.
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Figure 6 Analysis of proteasome function in Dendra-tau transgenic zebrafish. (A and B) Clearance kinetics of Dendra-tau in the
presence or absence of MG132. Treatment with MG132 blocks proteasome function and delays the clearance of WT-tau (A) but had no effect on
the clearance of A152T-tau (B) (n = 65 neurons/group; mean  SD; Student-Newman-Keuls one-way ANOVA, P5 0.01 and P5 0.001
versus untreated group). Note in A, the ‘WT-tau + MG132’ (denoted by black squares and black dashed line) overlaps with the ‘A152T-tau
untreated’ line (denoted by grey circles and grey solid line). In B, the ‘A152T-tau untreated’ line (denoted by the black triangles and solid black
line) overlaps with the ‘A152T-tau + MG132’ line (denoted by black squares and dashed black line). (C) Proteasome activity in lysates of WT-tau
and A152T-tau fish was measured using the synthetic Suc-LLVY-AMC substrate. A152T-tau fish showed significantly reduced chymotrypsin-like
activity compared to WT-tau fish (n = 20 fish from six independent clutches per group in triplicate; mean  SEM; two-tailed t-test: P5 0.05;
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cohorts with clinically-diagnosed or pathologically-con-
ﬁrmed dementia with Lewy bodies. However, Pastor
et al. (2016) did not show a signiﬁcant association between
p.A152T and Alzheimer’s disease, and the association with
FTD was of borderline signiﬁcance (OR = 2.03; 95%
CI = 0.95–4.34P = 0.063) (Pastor et al., 2016).
Using a large multinational consortium, we attempted to
clarify the situation with regard to FTD spectrum and other
clinical syndromes known to be caused by FTLD-tau. In
the present study, we ﬁnd signiﬁcant risk associations in
our independent FTD and PSP-S cohorts with the
p.A152T variant. This replicates the effect for FTD we re-
ported initially (Coppola et al., 2012) and is consistent with
the trend observed by Pastor et al. (2016). Thus, we feel
that this constitutes good genetic support for p.A152T as a
tauopathy risk variant. Previous neuropathologic analysis
of autopsies of individual patients carrying the p.A152T
MAPT variant have shown different types of abnormal
tau accumulation, some fulﬁlling criteria for corticobasal
degeneration, PSP (Kara et al., 2012), or pallidonigroluy-
sian atrophy (Graff-Radford et al., 2013), while others
were considered to be unclassiﬁable tauopathies (Kovacs
et al., 2011). It remains unclear whether and how the
MAPT variant relates to diseases without predominant
tau pathology, although we acknowledge that larger sam-
ples may be able to reveal associations with other condi-
tions, like Parkinson’s disease and Lewy body dementia.
Previous studies have suggested that p.A152T tau may
diminish tau binding to microtubules, while increasing tau
oligomer formation (Coppola et al., 2012) and cause
increased tau phosphorylation in induced pluripotent stem
cell-derived neurons, among other phenotypes. To test
p.A152T pathogenicity in vivo, we developed zebraﬁsh
models to compare WT-tau to A152T-tau alleles. The
A152T-tau ﬁsh have increased tau phosphorylation, insol-
uble tau and neuroﬁbrillary tangle formation associated
with increased caspase staining (apoptosis) and neurode-
generation. Similarly, the A152T-tau ﬁsh had overt mor-
phological and behavioural defects compared to the WT-
tau counterparts. Our data are compatible with the more
severe phenotypes seen in mouse models expressing A152T
compared to wild-type tau (Decker et al., 2016; Maeda
et al., 2016).
We characterized the expression levels of the two trans-
genes (WT-tau and A152T-tau) and have robustly demon-
strated that the pathology observed in ﬁsh expressing the
A152T-tau variant is not a consequence of higher mRNA
expression. However, we found protein levels of A152T-
tau to be increased at the times when the pathological
phenotypes manifest. Using a novel, in vivo protein clear-
ance assay, we found that A152T-tau had slower clearance
kinetics compared to WT-tau in vivo, and this could be
attributed to impaired proteasome function. These effects
of a disease-associated tau variant showing greater inhib-
ition on the proteasome activity than wild-type tau are
likely mediated via the same processes described recently
for the P301L autosomal dominant tau mutation (Myeku
et al., 2016) and this inhibition of proteasome activity may
provide a mechanism to account for the higher protein/
mRNA ratios observed in A152T mice compared to those
expressing WT-tau (Maeda et al., 2016).
This proteasome impairment may explain an important
conundrum; namely why the A152T variant has been asso-
ciated with TDP-43 and Lewy body/alpha-synuclein path-
ology in different isolated cases (Kara et al., 2012). While
these associations may be coincidence, the possibility that
A152T tau may be able to provoke the accumulation of
other intracytoplasmic proteins needs to be considered.
This is especially relevant given the association data of
Labbe et al. (2015) implicating A152T in alpha-synucleino-
pathies, and the multitude of papers showing associations
between the MAPT/tau haplotype and Parkinson’s disease
risk (Desikan et al., 2015). All of these studies raise the
question of how a tau variant may provoke the accumula-
tion of proteins besides tau.
We show that A152T-tau impairs proteasome activity,
and this causes the accumulation of proteasome substrates
(not only tau itself). Proteasome substrates also include
alpha-synuclein (Webb et al., 2003) and TDP-43 (Huang
et al., 2014). So, we propose that a primary consequence of
A152T-tau is to impair to activity of the proteasome, and
cause the accumulation of various proteasome substrates.
As this is a variant that acts via incomplete penetrance and
Figure 6 Continued
 P5 0.01 and P5 0.001 versus WT-tau). When treated with MG132, proteasome function is blocked in all genotypes [i.e. non-transgenic fish
(ve), WT-tau and A152T-tau], hence the grey lines overlap. (D and E) Western blots for the 1–7 proteasome subunits showed no difference
between WT-tau and A152T-tau fish indicating that the proteasome is structurally normal and equally abundant in both groups (lysates are the
same as used for C; all bands are specific and upper band was used for quantification; mean  SEM n = 6/group; two-tailed t-test). (F and G)
Transient expression of UbG76V-GFP (Dantuma et al., 2000) was used to measure proteasome function in vivo. In non-transgenic and WT-tau
transgenic fish, the GFP signal is detected at a low level under basal conditions but is increased in the presence of MG132. However, in A152T-tau
fish the basal level of GFP is higher than in non-transgenic and WT-tau fish and treatment with MG132 fails to increase the detected levels of GFP
(specific band found at 27 kDa, asterisk shows unspecific band in F; mean  SEM of three clutches per group, n = 20 fish per clutch in duplicate;
two-tailed t-test, P5 0.05 versus untreated group, P5 0.05 versus untreated WT-tau group, ##P5 0.001 versus untreated negative siblings).
(H and I) Higher levels of endogenous ubiquitinated proteins were detected in A152T-tau fish compared to WT-tau fish (minimum two inde-
pendent clutches per group, each analysed in triplicate, mean  SEM; two-tailed t-test, P5 0.05 and P5 0.01 versus untreated group,
P5 0.001 versus untreated WT-tau and ###P5 0.001 versus untreated negative siblings).
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Figure 7 Modulation of A152T-tau clearance and pathology by upregulation of autophagy. (A and B) Treatment of A152T-tau fish
with the autophagy inducers clonidine (A), rapamycin or rilmenidine (B), accelerated clearance kinetics of A152T-tau (mean  SD of n5 40
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(continued)
likely requires other genetic and environmental factors to
enable disease in humans, we hypothesize that, depending
on the genetic background effects on the biologies and me-
tabolism of other proteins like alpha-synuclein or TDP-43,
these could accumulate more rapidly than tau in some cases
with the A152T variant. A similar mechanism may be
relevant even to the situation of the tau haplotype and
alpha-synucleinopathies, as our data suggest that even over-
expression of wild-type tau in zebraﬁsh (which was not
associated with any gross phenotypes) led to some prote-
asome impairment, although this was less marked than
that seen with the A152T variant. Thus, our mechanistic
data allow an understanding of a mystery with regard
to the inﬂuence of tau on diseases other than pure
tauopathies.
As autophagy was not obviously perturbed in our model,
we tested whether enhancing tau clearance by upregulating
autophagy would be able to reduce the severity of the
A152T-tau phenotypes. Using both pharmacological and
genetic autophagy enhancers, we could demonstrate pheno-
typic amelioration in the A152T-tau ﬁsh as well as changes
in hyperphosphorylation and cell death, suggesting that this
therapeutic strategy deserves consideration. For therapeutic
efﬁcacy in humans, one may not require constitutive autop-
hagy upregulation, as pulsatile treatment may be effective
(Ravikumar et al., 2004; Rose et al., 2010). Importantly,
this strategy reduces the load of the toxic protein for the
relevant cells, thus targets the primary disease-initiating
factor.
In conclusion, we have performed a large genetic associ-
ation study that now replicates and conﬁrms the increased
risk for FTD and PSP-S conferred by the p.A152T tau
allele. We have supported these data with this rare variant
with animal modelling in zebraﬁsh that demonstrate clear
increased pathogenicity of this risk allele. Furthermore, our
data suggest that autophagy induction may be a suitable
therapeutic strategy for these tauopathies.
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neurons/group; Student-Newman-Keuls one-way ANOVA, /#P5 0.05; /##P5 0.01 P5 0.001 versus untreated). (C) Treatment with rapa-
mycin (rap), clonidine (clo) or rilmenidine (ril) also ameliorated morphological defects in A152T-tau transgenic fish (n = 6 independent experi-
ments, 20 fish/group, mean  SD; Student-Newman-Keuls one-way ANOVA, P5 0.05; P5 0.01 and P5 0.001 versus DMSO). (D)
Representative image showing rapamycin treatment reduced the proportion of abnormal A152T-tau fish. Scale bar = 3.5 mm. (E) Quantification of
the escape response measured in individual A152T-tau fish 3 dpf, treated with either DMSO, rapamycin, clonidine or rilmenidine. (n = 5 inde-
pendent experiments in triplicate, 15/group shown as mean  SD; two-tailed t-test: P5 0.05, P5 0.01 and P5 0.001 versus DMSO). The
treatment with autophagy upregulators improved the escape response deficit in A152T-tau fish. (F and G) Induction of autophagy by the addition
of rapamycin or rilmenidine to A152T-tau fish also reduced levels of phosphorylated tau at residues Ser202/Thr205 (AT8) and Ser396/Ser404
(PHF1) relative to total tau levels (n = 3 independent experiments in duplicate, 10/group shown as mean  SEM; two-tailed t-test: P5 0.05 and
P5 0.001 versus DMSO). (H and I) Treatment with autophagy upregulators results in less cell death. Rilmenidine treatment reduced the levels
of active caspase-3 (n = 4 independent experiments in triplicate, 10/group shown as mean  SEM; two-tailed t-test: P5 0.05 versus DMSO).
(J–N) Injection of an expression vector encoding zebrafish atg5 into A152T-tau fish embryos resulted in over-expression of Atg5 protein at 2 dpf
(J and K) (high and low exposure of the same blot presented; mean  SD, n = 6 independent clutches; two-tailed t-test, P5 0.05 versus control).
(J and L) The increase in Atg5 protein correlated with increase in LC3II, a well-characterized reporter for autophagosome number, demonstrating
that autophagy was upregulated in Atg5-injected fish (mean  SEM, n = 8 independent clutches; two-tailed t-test, P5 0.001 versus control). (M
and N) A consistent reduction in the number of offspring with morphological defects was observed in Atg5-injected fish compared to control
(uninjected) siblings. The percentage of normal fish changes from 52.43%  6.01 to 87.79%  4.87 after Atg5 injection and consequently, the
proportion of abnormal fish diminishes from 47.57%  6.01 to 12.21%  4.87 (mean  SEM of seven independent clutches; two-tailed t-test,
P5 0.001 versus control).
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